The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...

With a solid cash position and expected profitability by late 2026, Apellis stock is set for recovery. Read the latest ...

Can Boston stay on top in biotech? Find out on Sept 17, 6-9 p.m. EDT to explore talent shifts, funding, and Boston’s future.

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Astellas Pharma Inc. ADR company and executive profile by Barron's. View the latest ALPMY company infomation and executive bios.

In this Phase III trial, the Padcev-Keytruda combination used as both neoadjuvant and adjuvant therapy significantly improved event-free and overall survival, as well as pathologic complete response, ...

Pfizer (PFE) recently announced positive results from its Phase 3 EV-303 clinical trial in collaboration with Astellas Pharma ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

In the Phase III trial, the combination of Padcev and Keytruda improved event-free survival and overall survival in MIBC.

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...